SPOTLIGHT: Genentech touts vision drug

Macular degeneration patients treated with Lucentis saw their sight sharpen so radically that they could meet vision requirements for driving, researchers said. In the trial, about 40 percent of the 716 patients achieved vision of 20/40 or better after 12 months. Genentech has put the drug on the fast track for FDA approval. Story

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.